ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jemincare and GlaxoSmithKline side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

JemincareGlaxoSmithKline
studies on the registry374,198
open to participants now30136
phase 3 studies under way378
reach primary completion within a year668
programswith a study of their own in two years988+17 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJemincareGlaxoSmithKline
Phase 1

Jemincare: 5 of its 9 programs at phase 1

  1. JMKX000197phase 1
  2. JMKX003948phase 1
  3. Amiodaronephase 1
  4. JMKX005425phase 1
  5. JY1001phase 1
56%

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
Phase 200%

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%
Phase 3

Jemincare: 3 of its 9 programs at phase 3

  1. JMKX003142phase 3
  2. ozureprubartphase 3
  3. KRAS G12C Inhibitor JMKX001899phase 3
33%

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%
Approved, new studies

Jemincare: 1 of its 9 programs at approved, new studies

  1. sonidegibapproved, new study
11%

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jemincare3 readouts · 1 phase 3···

Jemincare, Feb ’27: 1 program whose next study reaches primary completion

  1. JMKX003142phase 3 · Feb 28 · NCT06800651
··

Jemincare, May ’27: 1 program whose next study reaches primary completion

  1. JY1001phase 1 · May 0 · NCT07848945

Jemincare, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ozureprubartphase 3 · Jun 7 · NCT07402213
····
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jemincare

New programs 1

  • JY1001phase 1 · first study · Sep 17 · Pain

Reached a new phase 1

  • JMKX003142phase 3 · Sep 7 · Polycystic Kidney, Autosomal Dominant

Study stopped 0

None

Primary completion later 0

None

GlaxoSmithKline

New programs 5

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionJemincareGlaxoSmithKline
Carcinoma, Non-Small-Cell Lungboth · compare here

Jemincare in Carcinoma, Non-Small-Cell Lung: 1 program

  1. KRAS G12C Inhibitor JMKX001899phase 3

Their studies: Jemincare’s studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Asthmaboth · compare here

Jemincare in Asthma: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Asthma in search

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

Breast Neoplasmsboth · compare here

Jemincare in Breast Neoplasms: 1 program

  1. sonidegibapproved, new study

Their studies: Jemincare’s studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Immune System Diseasesboth · compare here

Jemincare in Immune System Diseases: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Immune System Diseases in search

GlaxoSmithKline in Immune System Diseases: 2 programs

  1. isatuximabphase 2
  2. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Immune System Diseases in search

Polycystic Kidney, Autosomal Dominantboth · compare here

Jemincare in Polycystic Kidney, Autosomal Dominant: 2 programs

  1. JMKX003142phase 3
  2. Amiodaronephase 1

Their studies: Jemincare’s studies of Polycystic Kidney, Autosomal Dominant in search

GlaxoSmithKline in Polycystic Kidney, Autosomal Dominant: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Polycystic Kidney, Autosomal Dominant in search

Chronic Urticariaboth · compare here

Jemincare in Chronic Urticaria: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Chronic Urticaria in search

GlaxoSmithKline in Chronic Urticaria: 1 program

  1. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Chronic Urticaria in search

Rhinitis, Allergic, Perennialboth · compare here

Jemincare in Rhinitis, Allergic, Perennial: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Rhinitis, Allergic, Perennial in search

GlaxoSmithKline in Rhinitis, Allergic, Perennial: 1 program

  1. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Rhinitis, Allergic, Perennial in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Jemincare 4 of 9 · GlaxoSmithKline 65 of 88 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).